Expanded Carrier Screen by Next Generation Sequencing with Fragile X
Also known as: ECS SEQ FX
Use
This test provides a comprehensive analysis for carrier screening by detecting various genetic disorders, including Fragile X syndrome, through next-generation sequencing techniques. It is suitable for individuals who are pregnant or actively planning a pregnancy, or male partners of those who are pregnant. The test aims to identify carriers of genetic conditions that may not display symptoms themselves but have a risk of passing to offspring, allowing for informed genetic counseling and family planning.
Special Instructions
Not provided.
Limitations
The test detects a wide range of genetic disorders but may not encompass all possible genetic variations or mutations. Results could be affected by the quality of the DNA sample, and false negatives or positives are possible depending on the specific genetic variation. Ethnicity information is crucial for interpretation, and missing this data, Myriad defaults the interpretation based on Northern European ancestry. Limitations are also present in terms of detecting certain types of changes, such as large deletions or duplications.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
No genes
Gene
LOINC Codes
- 11526-1 - Pathology study
- 53039-4 - Gene dis anl carrier interp-Imp
Result Turnaround Time
17-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
1 mL
Container
Lavender (EDTA)
Patient Preparation
Patient must be at least 18 years of age, be pregnant, or be actively seeking/planning a pregnancy, or be a male partner of the pregnant patient.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant